Many supplements are available to the general public for a limited time on our SuppleNet page.
VOLUME 60 1999 SUPPLEMENT 1
Articles
3 Introduction. Pharmacoeconomics of
Treatment-Resistant Schizophrenia. M. Annette Hanson, M.D., Symposium Chair
[PDF]
4 The Economic Impact of Schizophrenia. Dorothy P. Rice
[Abstract]
[PDF]
7 Pharmacoeconomic Evaluation
of Treatments for Refractory Schizophrenia:
Clozapine-Related Studies. Dennis A. Revicki, Ph.D.
[Abstract]
[PDF]
12 New Antipsychotic Agents: Emerging Clinical Profiles. Peter F. Buckley, M.D.
[Abstract]
[PDF]
18 Clozapine for Refractory Schizophrenia:
The Illinois Experience. Robert W. Buckman, Ph.D., and Randy D. Malan, R.Ph.
[Abstract]
[PDF]
23 New vs. Old Antipsychotics:
The Texas Experience. William H. Reid, M.D., M.P.H.
[Abstract]
[PDF]
26 Pharmacoeconomics of
Schizophrenia in the 21st Century. M. Annette Hanson, M.D.
[Abstract]
[PDF]
28 Consensus Discussion.
[PDF]